SpectraMax i3 Multi-Mode Detection System
See how you can do more with your microplate reader than you ever imagined.
Watch Video
Bioanalysis of Oxytocin
Ultrasensitive Quantification Assay for Oxytocin in Human Plasma Using an LC/MS Microfluidics Platform
Watch Video

The Discoverome, creative destruction of barriers for faster to patient medicines R&D

By Chris Molloy
Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.

Pharma Derisking, approaches to reduce liability to major metabolically-driven causes of drug attrition

By Guy Webber
Intelligent application of early in vitro testing can help mitigate major drug development risks.

Spheroids rapidly becoming a preferred 3D culture format

By Dr John Comley
There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture.

Something old, something new... a marriage of technologies for immuno-oncology in vivo studies

By Dr Philip Dube
Discovering & validating novel therapeutic targets to add to the immuno-oncology arsenal requires refined preclinical models that meet needs for suitability, scalability & clinical relevancy throughout the phases of target discovery & drug validation.

Three-dimensional cell culture: a rapidly emerging technique for drug discovery

By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen
Past decades have witnessed significant efforts toward the development of 3D cell cultures. They are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.

Immuno-Oncology's Biomarker Dilemma How to add value in an uncertain development landscape

By Dr Rachel Laing and Olivier Lesueur
Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies.

Monitoring the balance between immune repression and stimulation in cancer immunotherapy

By Dr Peter Schulz-Knappe and Dr Georg Lautscham
Cancer remains one of the main causes of death worldwide, yet recent strides have been made in the form of new cancer immunotherapies.

Enzo Life Sciences Introduces Innovative Ultra-Sensitive Multiplex IHC Kit

Enzo Life Sciences is pleased to unveil their newest immunohistochemistry product, MULTIVIEW PLUS IHC Kit.

Owlstone Medical and Mayo Clinic Collaborate to Develop Pre-Endoscopic Test to Improve Effectiveness of Colonoscopy

Owlstone Medical, has announced it has entered into collaboration with Mayo Clinic, the leading US non-profit medical practice, education, and medical research group.

Cobra Biologics Embarks On £15m (165m SEK) Gene Therapy Manufacturing Operations Expansion

Cobra Biologics, has announced it is to expand operations at its sites in UK and Sweden to meet the increased demand of gene and immunotherapy companies to fast track their portfolios through to in-market supply.

UK’s innovation agency backs Plasticell to produce red blood cell substitute from pluripotent stem cells

Plasticell has announced it has secured Biomedical Catalyst funding of over £920,000 from Innovate UK to create a safe, effective red blood cell substitute for human clinical transfusion, in collaboration with stem cell scientists at the University of Edinburgh.

Lhasa and Optibrium Enter Research and Product Development Collaboration

Optibrium and Lhasa Limited, have announced they have formed a collaborative partnership to research next generation drug metabolism modelling.

Gyros Protein Technologies introduces a multi-species kit for pharmacokinetic studies

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays & leading provider of peptide synthesizers and reagents, have announced it has introduced a new kit for early-stage biotherapeutic pharmacokinetic (PK) studies.